ACOR - Acorda Therapeutics, Inc.

17.26
-0.340   -1.970%

Share volume: 11,619
Last Updated: 08-08-2023

PREVIOUS CLOSE
CHG
CHG%
$17.60
-0.34
-1.93%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Historical prices Events Documents Notes Dividends
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
14.70%
1 Month
31.39%
3 Months
3,455.56%
6 Months
1,695.92%
1 Year
3,855.06%
2 Year
382.19%
Key data
Stock price
$17.26
P/E Ratio 
-7.36
DAY RANGE
N/A - N/A
EPS 
-$2.59
52 WEEK RANGE
$0.26 - $18.20
52 WEEK CHANGE
$38.34
MARKET CAP 
428.343 M
YIELD 
N/A
SHARES OUTSTANDING 
24.338 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.59
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$12,733
AVERAGE 30 VOLUME 
$10,687
Company detail
CEO: Ronald Cohen
Region: US
Website: acorda.com
Employees: 130
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

Acorda Therapeutics, Inc. develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS) Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.

Recent news